Ranbaxy recalled 29790 packs of an allergy-relief drug manufactured by Ohm Labs plant of Ranbaxy in New Jersey in the US, due to defective packaging. Ranbaxy’s decision was confirmed by the United States Food and Drug Administration (USFDA) on 2 May 2014 that the company started recalling the drugs in February 2014.
The loratadine and pseudoephedrine sulphate with expiry date of September 2015 manufactured by Ohm Labs plant is being recalled. Ohm Labs is the only facility of the company making generics for the United States. In March 2014, Ranbaxy also recalled more than 64000 bottles of its generic version of Pfizer's Lipitor (atorvastatin) from US pharmacies due to a potential dose mix-up.
The Ranbaxy voluntarily recalled the medicine on the back drop of USFDA has banned all the four plants of Ranbaxy in India from exporting drugs to the US.
In 2008, USFDA banned the import of 30 generic drugs produced by Ranbaxy at the Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh and as well as from Mohali plant of Ranbaxy for violation of manufacturing norms.
In January 2014, the USFDA banned the import of products from Toansa plant of Ranbaxy in Punjab, India. The ban was imposed on account of safety and quality concerns. USFDA sighted eight lapses in maintaining standard that includes presence of flies in sample storage room, un-calibrated instruments in laboratory and non-adherence to sample analysis procedure.
In April 2014, Sun Pharmaceutical Industries Ltd acquired 100 percent of Ranbaxy in an all stock deal for 3.2 billion dollars. Sun Pharma may phase out the Ranbaxy brand in the US, although the name could be retained in other markets.
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.